Targeting Programmed Cell Death in Flap Ischemia/Reperfusion Injury

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Surgical Oncology

Background:

• Skin flaps are crucial for reconstructive surgery but are susceptible to necrosis from ischemia/reperfusion injury (IRI).
• Programmed cell death (PCD) pathways are key mechanisms underlying flap necrosis following IRI.
• Effective strategies to mitigate IRI-induced flap necrosis are critical for improving surgical success rates.

Purpose of the Study:

• To systematically review the mechanisms of programmed cell death (PCD) in ischemia/reperfusion injury (IRI) affecting skin flap survival.
• To summarize current and emerging therapeutic interventions targeting PCD modalities to prevent flap necrosis.
• To identify shared pathways and novel strategies for enhancing therapeutic outcomes in flap reconstruction.

Main Methods:

• Systematic literature review of studies investigating PCD mechanisms and therapeutic interventions in skin flap IRI.
• Analysis of preconditioning, systemic, and local drug delivery strategies targeting various PCD modalities.
• Identification of common PCD pathways and biomaterial-based therapies.

Main Results:

• Targeted therapies against specific PCD modalities show feasibility in preventing post-reconstructive flap necrosis.
• Interventions including preconditioning and targeted drug delivery can mitigate IRI-induced cell death.
• Identification of shared pathways across different PCD types offers potential for broad therapeutic application.

Conclusions:

• Targeting programmed cell death (PCD) is a viable strategy to prevent skin flap necrosis.
• Novel therapeutic approaches, including targeting common PCD pathways and utilizing biomaterials, can enhance flap survival.
• Further clinical research is warranted to translate these findings into effective treatments for flap necrosis.